Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phorbol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.63 |
| ▸ | PRKCG | P05129 | 5/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.63 |
| ▸ | PRKCB | P05771 | 4/20 | 0.63 |
| ▸ | PRKCH | P24723 | 4/20 | 0.63 |
| ▸ | PRKCI | P41743 | 4/20 | 0.63 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.63 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.63 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.63 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phorbol SCHEMBL22973790 | 0.98 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27419386 | 0.98 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL64353 | 0.98 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL28866474 | 0.98 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL7566989 | 0.93 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27478115 | 0.93 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL28465138 | 0.92 | PRKCA (0.56) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27450792 | 0.92 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL23610504 | 0.91 | PRKCA (0.61) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL10590327 | 0.91 | PRKCA (0.61) | PRKCAPRKCGPRKD3PRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1495254-A | NF-kB inhibition using caffeic acid phenethyl ester derivatives, capsaicin and resiniferatoxin | 研究发展基金会 | 2004-05-12 | — | — | CN | claimed |
| CN-1478149-A | Method for screening physiologically active substance | 宝生物工程株式会社 | 2004-02-25 | — | — | CN | claimed |
| CN-104136457-A | FUSION PROTEIN COMPRISING INTERLEUKIN 10 AND INTERLEUKIN 4 | UMC UTRECHT HOLDING BV | 2014-11-05 | — | — | CN | disclosed |
| CN-103930568-A | Methods for treating, diagnosing and monitoring Alzheimer's disease | HOFFMANN LA ROCHE | 2014-07-16 | — | — | CN | disclosed |
| CN-102203078-B | P38 MAPK kinase inhibitor | RESPIVERT LTD | 2014-06-25 | — | — | CN | disclosed |
| CN-103703023-A | Shortened tetranectin-apolipoprotein A-I fusion proteins, lipid particles containing same, and uses thereof | HOFFMANN LA ROCHE | 2014-04-02 | — | — | CN | disclosed |
| CN-103351389-A | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC | 2013-10-16 | — | — | CN | disclosed |
| CN-102822332-A | Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts | STEM CELL & REGENERATIVE MEDICINE INTERNATIONAL INC | 2012-12-12 | — | — | CN | disclosed |
| CN-102712645-A | Compound (I) | RESPIVERT LTD | 2012-10-03 | — | — | CN | disclosed |
| CN-102317446-A | Isolating monocyte crowd and relevant treatment are used | SCRIPPS RESEARCH INST | 2012-01-11 | — | — | CN | disclosed |
| CN-102292333-A | Protein kinase c inhibitors and uses thereof | — | 2011-12-21 | — | — | CN | disclosed |
| CN-1278794-A | Substituted 2-hydroxyindole derivatives as inhibitors of protein tyrosine kinases and protein serine/threonine kinases | GLAXO GROUP LTD (GB) | 2001-01-03 | — | — | CN | disclosed |
| CN-1202906-A | Type CC chemokine-like protein | SHINOGI CO (JP) | 1998-12-23 | — | — | CN | disclosed |
| CN-1139917-A | Arylalkyl amine compounds active at calcium receptors | NPS PHARMA INC (US) | 1997-01-08 | — | — | CN | disclosed |
| CN-1031132-C | Carbocyclic adenosine analogs useful as immunosuppressants | MARION MERRELL DOW INC (US) | 1996-02-28 | — | — | CN | disclosed |
| CN-1028542-C | Anticancer antibiotic MZ43-37F11 substance, the production and uses thereof | ZAIDAN HOJIN BISEIBUTSU (JP) | 1995-05-24 | — | — | CN | disclosed |
| CN-1059909-A | The carbocyclic ring neplanocin of new useful as immunosuppressants | MARION MERRELL DOW INC (US) | 1992-04-01 | — | — | CN | disclosed |
| CN-1047696-A | New antitumor antibiotics MI43-37F11 material, its production method and application | ZAIDAN HOJIN BISEIBUTSU (JP) | 1990-12-12 | — | — | CN | disclosed |
| CN-1036794-A | Method for increasing yield of cytokinin | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1989-11-01 | — | — | CN | disclosed |
| CN-85107235-A | As the replacement cinnamyl-2 of anti-inflammatory agent, the manufacture method of 3-Dihydrobenzofuranes and analogue | — | 1987-04-01 | — | — | CN | disclosed |